Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...